ArticleInternational journal of general medicine2026
Association Between Genotype and Plasma Levels of EPCR in Type 2 Diabetes Mellitus in Jazan Region, Saudi Arabia: A Case-Control Study.
Article in International journal of general medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Type 2 diabetes mellitus (T2DM) is a major health burden in Saudi Arabia. Its prevalence is estimated at 16.4% to 28% among adults. It is characterized by chronic hyperglycemia inducing low-grade inflammation, which drives various physiological changes, including endothelial dysfunction. The endothelial protein C receptor (EPCR) is a membrane-bound receptor expressed on normal endothelial cells and is released upon endothelial dysfunction into the blood as soluble EPCR (sEPCR). Increased cleavage and release of EPCR is associated with the EPCR rs867186 polymorphism. Therefore, the current study aimed to investigate the pattern and frequency of EPCR rs867186 polymorphism and plasma levels of sEPCR in patients with T2DM and healthy controls. Materials and Methods: The current case-control study was performed in Jazan region, Saudi Arabia. Two hundred and thirty-four blood samples were collected from the 136 patients with T2DM and 98 healthy controls for DNA analysis and hematological and biochemical assessments. Results: The plasma levels of sEPCR were significantly elevated in T2DM patients compared to controls, despite no association being found between sEPCR levels and the genotype in either cohort. The pattern of EPCR rs867186 polymorphism revealed AA in 83.8% (n=196) and AG in 16.2% (n=38) of total cohorts (n=234), with comparable genotype distribution between patients and controls. Conclusion: This study highlights a significant elevation in plasma levels of sEPCR in patients with T2DM, indicating increased shedding of membrane EPCR and suggesting endothelial dysfunction. Importantly, the levels of sEPCR were not associated with rs867186 polymorphism. These findings suggest that sEPCR could be a useful biomarker for predicting early inflammation and endothelial dysfunction in T2DM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.